Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia

This publication has 10 references indexed in Scilit:

• Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study Commentary: Role of other genes and environment should not be overlooked in monogenic disease
  BMJ, 2001
• Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial
  The Lancet, 2001
• Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering
  The American Journal of Cardiology, 2000
• Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia
  Atherosclerosis, 2000
• Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management
  Atherosclerosis, 1999
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
  New England Journal of Medicine, 1995
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.
  BMJ, 1991
• Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia
  Circulation, 1974